Verona Pharma plc (VRNA)
Fuera de horario:
Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom
44 20 3283 4200
https://www.veronapharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 79
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David S. Zaccardelli Pharm.D. | President, CEO & Executive Director | 1.27M | N/D | 1964 |
| Mr. Mark W. Hahn | Chief Financial Officer | 858.29k | N/D | 1963 |
| Dr. Kathleen A. Rickard M.D. | Chief Medical Officer | 650.83k | N/D | 1958 |
| Mr. Andrew Fisher | General Counsel | N/D | N/D | 1970 |
| Ms. Victoria Stewart | Director of Communications | N/D | N/D | N/D |
| Mr. Matthew Casbon | VP of Sales, Marketing & Training | N/D | N/D | N/D |
| Ms. Ostra Jewell | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Tara Rheault M.P.H., Ph.D. | Chief Development Officer | N/D | N/D | 1977 |
| Mr. Christopher Martin | Chief Commercial Officer | N/D | N/D | N/D |
| Ms. Caroline Diaz | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Descripción
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de Verona Pharma plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
